Off-Trial Evaluation of the B cell-Targeting Treatment in the Refractory Cases of Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis: Long-Term Follow-Up from a Single Centre

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis

(2011) M.-J. C. J. Guerry et al.   RHEUMATOLOGY

The American College of Rheumatology 1990 criteria for the classification of vasculitis: Patients and methods

(2010) Daniel A. Bloch et al.   ARTHRITIS AND RHEUMATISM

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

(2010) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

(2010) Rachel B. Jones et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis

(2009) Simon R. J. Taylor et al.   ARTHRITIS AND RHEUMATISM

B-cell depletion with rituximab for refractory head and neck Wegener’s granulomatosis: a cohort study

(2009) M. Martinez Del Pero et al.   CLINICAL OTOLARYNGOLOGY

B-Cell Depletion in Wegener’s Granulomatosis

(2008) Claas H. Hinze et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener’s granulomatosis: a case report

(2008) Seido Ooka et al.   Modern Rheumatology